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Abstract
Background: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen
activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with
an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study
was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and
interrelationship between PAI-1and tPA activities and antigens in Malaysian T2D and normal subjects.
Methods: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as
serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D
subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 non-
diabetic MetS subjects.
Results: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 × 10
-19) and non-diabetic subjects
with MetS (P = 3.0 × 10
-15), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal
subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 × 10
-24), T2D without MetS
(P = 1.3 × 10
-13) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects
were related to insulin resistance (P = 2.2 × 10
-4; 0.007). Additionally, the PAI-1 activity was associated with an
increased waist circumference (P = 2.2 × 10
-4) and decreased HDL-c (P = 0.005), whereas the tPA activity was
associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen
(R
2 = 0.695, P = 1.1 × 10
-36) in diabetic subjects. The tPA activity negatively correlated with its antigen (R
2 = -0.444,
P = 7.7 × 10
-13) in normal subjects and with the PAI-1 activity and antigen (R
2 = -0.319, P = 9.9 × 10
-12; R2 = -0.228,
P = 3.4 × 10
-6) in diabetic subjects.
Conclusions: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in
Malaysian subjects.
Background
Central obesity, hyperglycaemia, high triglycerides (TG),
low high-density lipoprotein cholesterol (HDL-c) and
hypertension, all are well-documented risk factors for
type 2 diabetes (T2D) and cardiovascular diseases(CVD)
[1]. The constellation of these metabolic abnormalities
(known as a metabolic syndrome (MetS) or insulin resis-
tance syndrome) increases the risk of T2D and CVD.
The number of individuals with the MetS has increased
globally during the past two decades, and this increase
is associated with the worldwide epidemic of obesity
and diabetes [2]. Obesity and physical inactivity are the
driving forces for MetS and a person with MetS has 5-
fold higher relative risk to develop diabetes [3] and 2.5
fold higher to develop CVD [4,5]. Overweightedness and * Correspondence: zalhamodi@yahoo.com; sekaran@um.edu.my
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terol, TG and impaired glucose tolerance (IGT) [6].
Plasminogen activator inhibitor-1 (PAI-1) is the pri-
mary physiological inhibitor of endogenous fibrinolysis
that acts via inhibition of the tissue plasminogen activa-
tor (tPA) and the urokinase type activator (uPA), often
leading to fibrin accumulation in basement membranes
and interstitial tissues [7-9]. Elevations in plasma PAI-1
appear to compromise normal fibrin clearance mechan-
isms and promote thrombosis. The plasminogen activa-
tors (t-PA and u-PA) convert plasminogen to plasmin,
which is involved in fibrinolysis, tissue remodelling and
cell migration [10]. In addition to its role in intravascu-
lar fibrinolysis, PAI-1 is also involved in cell-associated
proteolysis, cell migration, and tissue remodelling play-
ing a role in pathological processes such as cancer cell
invasion, metastasis and inflammation [11,12]. The
majority of tPA in the blood is bound to its primary
inhibitor, PAI-1[13].
In large epidemiological studies elevated plasma PAI-1
has been demonstrated in various subgroups as an
important feature of T2D and MetS [14-20] and this
elevation may contribute to a thrombotic tendency
[7-9,15,21]. This elevation precedes coronary artery dis-
ease [22] and even predicts the occurrence of first acute
myocardial infarction and reinfarction [23-25]. Remark-
ably, the predictive ability of PAI-1 disappears after
adjustment for markers of the MetS [26,27], suggesting
that the MetS is a prerequisite to high plasma PAI-1
levels in patients prone to atherothrombosis. Moreover,
it has been hypothesized that PAI-1 participates in the
development of key features of the MetS. The circulat-
ing PAI-1 levels are positively associated with obesity
and insulin resistance [28-30].
tPA activity may be an independent and early marker
for asymptomatic lower extremity arterial disease in
T2D [18,31]. Plasma tPA activities and the capacity of
endothelial cells to secret tPA in response to a fibrino-
lytic stimulus were also reported to be decreased in
adults with diabetes [15]. Elevated plasma tPA antigens
have been reported to be associated with insulin resis-
tance, T2D, and obesity [14,18] and increased risk of
CHD [32].
The aim of this study was to investigate the associa-
tion of the plasma activities and antigens of PAI-1 and
tPA, with T2D and MetS and to study the relationship
between activities and antigens of PAI-1 and tPA.
Materials and methods
Subjects and data collection
This study involved diabetic patients with and without
MetS and non-diabetic subjects with MetS receiving
treatment at the University Malaya Medical Centre
(UMMC), Kuala Lumpur. Normal subjects without
diabetes and MetS (the control group) in Klang Valley,
Kuala Lumpur were recruited. The study was approved
by the Medical Ethics Committee of University Malaya
Medical Centre. Written informed consent was obtained
from each subject. Patients with acute or chronic infec-
tions, severe medical conditions (malignancy, renal
failure, liver cirrhosis, connective tissue disease, and
chronic congestive heart failure) and pregnant women
were excluded from the study.
Blood pressure (BP) measurements were taken from
each patient’s right arm in the seated position by using
an Omron IntelliSense Automatic Blood Pressure Moni-
tor after 10 min of rest in a quiet room in the morning.
Two to three successive BP readings were obtained at
5-min intervals and averaged. Body weight and height
were measured in the fasting state without shoes in the
morning, and BMI was computed as weight in kilograms
(kg) divided by height in meters squared (m
2). Waist cir-
cumference was measured midway between the lower
rib margin and the superior iliac spine at the end of
gentle expiration in a standing position.
Fasting venous blood (10ml) was collected from each
subject within a 2-hour window (8:00 to 10:00 AM)
after 15 minutes rest, because of the diurnal variation of
plasma PAI-1 [33]. The collected blood immediately
taken into four labelled Vacutainer tubes, 0.109M
trisodium citrate (for tPA and PAI-1 antigens and tPA/
PAI-1 complex analysis), acidified 0.5M sodium citrate
(for tPA and PAI-1 activities), sodium fluoride (for glu-
cose measurement) and plain tubes (for insulin and lipid
profile). The plasma/serum of trisodium citrate and
plain tubes were separated gently within 30 minutes by
using Allerga R X-12R centrifuge (Beckman Coulter. Inc
US) for a 15 min at 2500-3000 × g at 4°C. Then the
plasma/serum was separated into corresponding micro
tubes and immediately kept at -80°C until analysis.
Biochemical Analyses
Serum TG, HDL-c and plasma glucose (FPG) were mea-
sured by an automated analyzer Dimension
® RxL Max
®
Integrated Chemistry System. Insulin was measured by
ADVIA Centaur assay XP Immunoassay System
(Siemens Healthcare Diagnostics Inc. Deerfield, IL
USA). All these investigations were done at Clinical
Diagnostic Laboratory of the University Malaya Medical
Centre (UMMC), Kuala Lumpur. Insulin resistance (IR)
and Insulin sensitivity (IS) were calculated using the
Homeostasis Model Assessment (HOMA2) Calculator
v2.2 which is available from Oxford Centre for Diabetes,
Endocrinology and Metabolism.
Plasma PAI-1 antigen was measured by TintElize
®
PAI-1 antigen ELISA test from Biopool (Trinity Biotech
Inc. USA, Jamestown, NY). PAI-1 activity, tPA activity
and antigen and tPA/PAI-1complex were measured by
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complex human assays respectively, (Molecular Innova-
tions, Inc. Peary Court, Novi, MI USA) according to the
manufacturer’s instructions. Plates were read at 450nm
except the PAI-1 antigen plate which was at 490nm
using a microplate reader (BioRad, USA).
Statistical Analyses
The results were analyzed by the SPSS 11.5 (Social
Package of Statistical Science) computer program by
LEAD Technologies; Inc. USA). The missing data were
listwise deleted (when any of the variables were missing,
the entire observation was omitted from the analysis).
The age, body mass index (BMI), waist, systolic blood
pressure (SBP), diastolic blood pressure (DBP), TG,
HDL-c, FBS, insulin, IS, IR, PAI-1 and tPA activities and
antigens and tPA/PAI-1 complex were log transformed
because they were not normally distributed. These
parameters means and 95% confidence intervals were
transformed back and reported as geometric means. The
association of PAI-1 and tPA activities and antigens and
tPA/PAI-1 complex with T2D and MetS were assessed
by univariate analyses (general linear model) adjusted
for age, gender and race as covariates. The association
of fibrinolytic PAI-1 and tPA activities and antigens
with MetS parameters; (BMI, waist, SBP, DBP, TG,
HDL-c, FBS, insulin, IS and HOMA (IR) (dependent
variables) were analysed by hierarchical linear regression
adjusted for age, gender and race as covariates in nor-
mal subjects. The interrelationship between fibrinolytic
parameters; PAI-1 and tPA activities and antigens and
tPA/PAI-1 complex in normal and T2D subjects were
first evaluated by linear regression. This evaluation
showed that (BMI, HDL-c and IR), (HDL-c and IR),
(FBS), (Age and IS) and (BMI) were significantly asso-
ciated with PAI-1 activity, PAI-1 antigen, tPA activity,
tPA antigen and tPA/PAI-1 complex respectively. Then
the correlation of fibrinolytic parameters with each
other re-evaluated by hierarchical linear regression con-
trolled for those corresponding confounder in addition
to age, gender and race.
Results
Of five hundred normal subjects freely respondents, only
190 were recruited for the study. After biochemical tests
and application of IDF criteria for MetS diagnosis [34],
131 subjects were revealed as normal without diabetes
and MetS (the control group). One hundred and one
subjects out of 142 participants under treatment for
hyperlipidaemia and/or hypertension at University
Malaya Medical Centre (UMMC) were diagnosed as
non-diabetic MetS subjects. Three hundred and three
subjects who were previously diagnosed as T2D were
participated in this study. Of these, 227 had MetS and
76 did not have MetS as defined by the IDF criteria for
MetS diagnosis.
The demography and biochemical parameters of the
subjects are shown in table 1. The fibrinolytic para-
meters, PAI-1 and tPA activities and antigens and tPA/
PAI-1 complex assessed by general linear model (uni-
variate) are shown in table 2. In general, the plasma
levels of PAI-1 activity and tPA antigens were higher in
T 2 Dp a t i e n t sc o m p a r e dt on o r m a ls u b j e c t s( P=1 . 7×
10
-8,3 . 0×1 0
-24 respectively) whereas the PAI-1 antigen
and tPA activity (P = 0.01, 0.03 respectively) were lower
in T2D. There was no difference in tPA/PAI-1 complex
between T2D and control subjects. On the other hand,
the plasma PAI-1 activity was higher in non-diabetic
MetS (P = 3.0 × 10
-15,1 . 5×1 0
-18)a n dT 2 Dw i t hM e t S
subjects (P = 9.8 × 10
-19,1 . 8×1 0
-21)c o m p a r e dt on o r -
mal and T2D without MetS subjects respectively. Never-
theless, there was no difference in PAI-1 activity
between the normal and T2D without MetS subjects
and between non-diabetic MetS and T2D with MetS
subjects (Table 2). However, the PAI-1 antigen was not
significantly higher in non-diabetic MetS and signifi-
cantly lower in T2D without MetS (P = 2.2 × 10
-9) com-
pared to normal subjects. The results further showed
that PAI-1 antigen was lower in both T2D without
MetS (P = 6.9 × 10
-13) and T2D with MetS (P = 0.02)
compared to non-diabetic MetS subjects. Besides, it was
higher in T2D with MetS (P = 5.1 × 10
-10) compared to
T2D without MetS subjects. The tPA activity was lower
in T2D with MetS compared to normal, non-diabetic
MetS and T2D without MetS groups (P = 0.003, 0.002,
6.7 × 10
-5) respectively. On the other hand, there were
no differences in the tPA activities between the other
groups. In contrast, the tPA antigen was higher in non-
diabetic MetS, T2D without MetS and T2D with MetS
compared to control group (P = 0.002, 1.3 × 10
-13, 8.9 ×
10
-24) respectively. In addition, the tPA antigen was
higher in T2D without MetS and T2D with MetS
compared to non-diabetic MetS group (P = 1.3 × 10
-6,
1.3 × 10
-12) respectively. Further the results showed that
tPA/PAI-1 complex was lower in the T2D without
MetS compared to normal (P = 0.04), non-diabetic
MetS (P = 0.02) and T2D with MetS (p = 0.001) groups
while there were no differences in the tPA/PAI-1 com-
plex between the other groups.
The association of fibrinolytic variables (PAI-1 and
tPA activities and antigens) with MetS parameters was
evaluated in normal subjects, and the results are
depicted in table 3. The activity and antigen of PAI-1
associated with increased insulin levels (b = 1.941,
P = 1.2 × 10
-4;b=1 . 6 1 4 ,P=0 . 0 1 5 ) ,i n s u l i nr e s i s t a n c e
(b = 1.393, P = 2.2 × 10
-4; b = 1.318, P = 0.007), and
decreased insulin sensitivity (b = -1.963, P = 1.1 × 10
-4;
b = -1.637, P = 0.012). Furthermore, the PAI-1 activity
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1.159, P = 2.2 × 10
-4) and BMI (b = 1.199, P = 0.001))
and decreased HDL-c levels (b = -1.125, P = 0.005.).
Although the tPA activity counteracts the PAI-1 activity
which associated with decreased FBG (b = -1.079, P =
0.028), the tPA antigen showed no association with
MetS parameters.
The interrelationship between activities and antigens
of PAI-1 and tPA and tPA/PAI-1 complex parameters
were further assessed in normal and T2D groups as
shown in Table 4 and 5 respectively. Among normal
subjects, the tPA activity negatively correlated with its
antigen (r
2 =- 0 . 4 4 ,P=7 . 7×1 0
-13) and weakly corre-
lated with tPA/PAI-1 complex (r
2 = -0.090, P = 0.001).
In contrast, the tPA antigen positively correlated with
tPA/PAI-1 complex (r
2 =0 . 2 0 2 ,P=3 . 5×1 0
-7). Unlike
normal subjects, there was a good correlation between
fibrinolytic parameters in T2D, the PAI-1 activity well
and positively correlated with its antigen (r
2 =0 . 7 0 ,P=
1.1 × 10
-36), and negatively correlated with tPA activity
(r
2 = -0.32, P = 9.9 × 10
-12). A similar correlation was
shown between PAI-1 antigen and tPA activity (r
2 =
-0.23, P = 3.4 × 10
-6). The pattern of tPA antigen corre-
lation with tPA/PAI-1 complex among T2D was similar
to that in normal subjects, but it was a weak correlation
(r
2 = -0.20, P = 3.5 × 10
-7;r
2 = 0.06, P = 7.9 × 10
-5).
Discussion
The Association of fibrinolytic parameters with T2D and
metabolic syndrome were studied; a higher PAI-1 activ-
ity is associated with T2D with MetS and MetS (nondia-
betic), which is characterized by the presence of
Table 1 Demography and Biochemical parameters among normal, non-diabetic metabolic syndrome and type 2
diabetes with and without metabolic syndrome groups
Parameters Normal (n = 131) Non-diabetic MetS
(n = 101)
Type 2 diabetes
without MetS (n = 76) with MetS (n = 227)
Gender% Male/
Female
18.5/29.2 23.9/14.8 17.7/11.3 39.9/44.7
Malay 25.9 17.5 13.7 43.0
Races % Chinese 36.1 22.1 14.8 27.0
Indian 12.1 18.8 14.8 54.4
Age (yrs) 47.2(44.9-49.7) 52.1(50.0-54.3) 49.8(47.6-52.1) 51.4(50.5-52.4)
p-value
a0.003
a0.349
a0.002
Body Mass Index (kg/m2) 22.7(22.1-23.3) 27.2(26.4-28.0) 23.34(22.5-24.3) 29.8(29.2-30.3)
p-value
a3.8 × 10
-13 a0.515,
b6.2 × 10
-10 a3.8 × 10
-13,
b3.2 × 10
-6,
c3.8 × 10
-13
Waist circumference (cm) 79.2(77.4-81.1) 94.5(92.8-96.3) 82.9(80.7-85.2) 98.6(97.4-99.7)
p-value
a3.8 × 10
-13 a0.02,
b4.2 × 10
-13 a3.8 × 10
-13,
b0.006,
c3.8
×1 0
-13
Diastolic Blood Pressure
(mmHg)
80.0(78.4-81.5) 85.6(83.6-87.6) 79.3(77.1-81.5) 83.1(81.7-84.5)
p-value
a1.7 × 10
-4 a0.966,
b2.3 × 10
-4 a0.02,
b0.004,
c0.02
Systolic Blood Pressure (mmHg) 130(127-134) 139(136-143) 129(125-134) 136(134-139)
p-value
a0.002
a0.965,
b0.002
a0.02,
c0.02
Triglyceride (mmol/l) 1.08(1.00-1.17) 1.59(1.46-1.72) 1.38(1.19-1.57) 1.78(1.66-1.91)
p-value
a1.6 × 10
-6 a0.02
a3.6 × 10
-13,
c0.001
High Density Lipoprotein
(mmol/l)
1.54(1.48-1.61) 1.26(1.20-1.31) 1.22(1.15-1.29) 1.15(1.11-1.18)
p-value
a1.2 × 10
-10 a2.6 × 10
-12 a4.8 × 10
-13,
b0.008
Fasting Blood Glucose (mmol/l) 5.02(4.93-5.10) 5.36(5.23-5.49) 8.05(7.41-8.74) 7.74(7.39-8.11)
p-value 0.24
aa 3.8 × 10
-13,
b3.8 × 10
-13 a3.8 × 10
-13,
b3.8 × 10
-13
Insulin (pmol/l) 45.7(41.7-50.1) 77.3(69.6-85.8) 63.7(52.9-76.5) 120(110-131)
p-value
a7.3 × 10
-9 a0.002
a4.1 × 10
-13,
b5.0 × 10
-8,
c1.4 × 10
-12
Insulin resistance (IR) 0.91(0.83-1.01) 1.53(1.37-1.69) 1.49(1.24-1.77) 2.59(2.38-2.81)
p-value
a1.0 × 10
-6 a3.2 × 10
-5 a4.1 × 10
-13,
b2.5 × 10
-12,
c3.8 × 10
11
The result presented as geometric mean and 95% confidence interval of mean,
avs control group:
bvs non-diabetic metabolic syndrome group:
cvs type 2
diabetes without metabolic syndrome which evaluated by ANOVA. Bolt values are significant. MetS: metabolic syndrome.
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agreement with other studies [35-40]. The plasma PAI-1
circulates in two states, active and latent. Active PAI-1
is bound to vitronectin (VN) [41,42] (the net molecular
weight of PAI-1/vitronectin, ~125,000) while latent PAI-
1 is unbound (MW ~50,000). The plasma vitronectin
levels are increased in diabetes with nephropathy [43].
T2D subjects with renal failure were excluded from this
study. However, nephropathy in T2D starts from the
early stage of development diabetes. Thus the latent
PAI-1 may be excreted in urine in quantities more than
PAI-1/vitronectin complex, which may result in an
increase in the ratio of active to latent PAI-1 in T2D
compared to normal subjects. This may explain why
PAI-1 antigen is lower in T2D while PAI-1 activity is
higher.
The Association of fibrinolytic parameters with MetS
parameters was assessed in normal (control subjects),
since the diabetic and non-diabetic MetS under treat-
ment. There was a clear trend shows increasing of PAI-
1 activity with increased insulin resistance, waist circum-
ference, BMI, and decreased HDL-c. This would also
explain the non-association of PAI-1 activity in subjects
with T2D but without MetS.
PA1-1 is partly synthesised in fat cells, and its activity
is related to abdominal obesity as mirrored by the high
waist circumference [44]. In this regard, lipid infusion in
normal subjects to the levels observed in T2D, and
Table 2 Comparison of fibrinolytic PAI-1 and tPA between normal, non-diabetic metabolic syndrome, type 2 diabetes
with and without metabolic syndrome and total type 2 diabetes groups
Parameters Normal (n = 131) Non-diabetic MetS
(n = 101)
Type 2 diabetes Total Type 2
diabetes (n = 303)
without MetS
(n = 76)
with MetS (n = 227)
PAI-1 activity (IU/ml) 12.8(11.1-14.7) 28.7(25.1-32.8) 11.0(9.37-12.9) 29.0(26.1-32.1) 21.7(19.7-23.9)
p-value
a3.0 × 10
-15,
c1.5 ×
10
-18
a0.167
a9.8 × 10
-19,
c1.8 × 10
-21 a1.7 × 10
-8,
b0.02
PAI-1 antigen (ng/ml) 30.2(27.1-33.7) 33.0(29.7-36.6) 18.2(16.2-20.6) 28.4(26.5-30.5) 25.4(23.9-27.1)
p-value
a0.259
a2.2 × 10
-9,
b6.9 × 10
-13
b0.02,
c5.1 × 10
-10 a0.01,
b4.7 × 10
-5
tPA activity (U/ml) 3.49(3.11-3.92) 3.51(3.14-3.91) 3.91(3.42-4.47) 2.82(2.58-3.07) 3.11(2.89-3.34)
p-value
a0.965
a0. 206
a0.003,
b0.002,
c6.7 × 10
-5 a0.03,
b0.03
tPA antigen (ng/ml) 4.62(4.10-5.21) 5.99(5.35-6.70) 9.15(8.04-10.4) 9.85(9.14-10.6) 9.67(9.07-10.31)
p-value
a0.002
a1.3 × 10
-13,
b1.3 × 10
-6
a8.9 × 10
-24,
b1.3 × 10
-12 a3.0 × 10
-24,
b1.7 × 10
-12
tPA/PAI-1 complex (ng/ml) 3.50(2.89-4.23) 3.57(2.97-4.30) 2.59(2.09-3.20) 3.91(3.46-4.42) 3.52(3.17-3.92)
p-value
a0.879
a0.04,
b0.02
a0.336,
c0.001
a0.94
The result presented as geometric mean and 95% confidence interval of mean adjusted for age, gender and race,
avs control group:
bvs non-diabetic metabolic
syndrome group:
cvs type 2 diabetes without metabolic syndrome which evaluated by univariate (General Linear Model). Bolt values are significant. MetS:
metabolic syndrome.
Table 3 Association of fibrinolytic PAI-1 and tPA with metabolic syndrome parameters among normal subjects
(n = 131)
Metabolic syndrome Parameters PAI-1 activity
b (P-value)
PAI-1 antigen
b (P-value)
tPA activity
b (P-value)
tPA antigen
b (P-value)
Body Mass Index (kg/m2) 1.199 (0.001) 1.079 (0.199) -1.109 (0.104) -1.021 (0.783)
Waist circumference (cm) 1.159 (2.2 × 10
-4) 1.057 (0.213) -1.033 (0.496) -1.035 (0.543)
Diastolic Blood Pressure (mmHg) -1.038 (0.342) -1.014 (0.763) 1.064 (0.185) 1.028 (0.607)
Systolic Blood Pressure (mmHg) -1.009 (0.846) 1.007 (0.889) 1.074 (0.198) 1.084 (0.195)
Triglyceride (mmol/l) 1.119 (0.165) -1.012 (0.899) 1.064 (0.558) 1.127 (0.331)
HDL- cholesterol (mmol/l) -1.125 (0.005) -1.067 (0.166) -1.076 (0.174) -1.016 (0.807)
Fasting Blood Sugar (mmol/l) 1.047 (0.092) 1.079 (0.02) -1.079 (0.028) 1.023 (0.583)
Insulin (pmol/l) 1.941 (1.2 × 10
-4) 1.614 (0.015) -1.236- (0.312) 1.288 (0.298)
Insulin Sensitivity (%) -1.963 (1.1 × 10
-4) -1.637 (0.012) 1.265 (0.266) -1.294 (0.289)
Insulin Resistance 1.393 (2.2 × 10
-4) 1.318 (0.007) -1.119 (0.305) 1.135 (0.313)
Result presented as b (P-value) assessed by linear regression, adjusted for age, gender and race. Bolt values are significant. b: coefficient for the relationship
between the dependent variable “metabolic syndrome parameters” and the independent variable “fibrinolytic PAI-1 and tPA parameters”. The positive sign of the
coefficient implies a direct relationship, and the negative sing implies an inverse relationship.
Al-Hamodi et al. Cardiovascular Diabetology 2011, 10:23
http://www.cardiab.com/content/10/1/23
Page 5 of 9obesity resulted in increased PAI-1 concentration by 2
fold [45]. Dysfunctions in the fibrinolytic and endothelial
system precede the development of overt T2D, which
increases the risk of atherothrombotic disease long
before overt diabetes is evident [45-47]. In addition,
PAI-1 may predict T2D independent of insulin resis-
tance and other known risk factors for diabetes, which
may be due to increase in PAI-1 activity influenced by
PAI-1 gene polymorphisms, adrenal steroids and angio-
tensin II activity [16,17]. The PAI-1 antigen levels were
low in T2D with MetS and much lower in T2D without
MetS. This finding can be partially explained by the
high correlation between PAI-1 activity and its antigen
in T2D (but not in normal subjects). On the other hand,
PAI-1 activity was remarkably high in T2D with MetS
but was normal in T2D without MetS. The high con-
centration of tPA antigen was mainly associated with
T2D without effect of MetS parameters which in agree-
ment with Eliasson et al, study [48]. The mechanism
that explains this elevation of tPA antigen in T2D is yet
unclear. The PAI-1 activity is negatively correlated with
tPA activity, which may reflect the low tPA activity in
T 2 Dw i t hM e t Sb u tn o ti nT 2 Dw i t h o u tM e t S .H i g h
PAI-1 antigen inhibits tPA released from the vessel
walls and decreased levels of free PA, i.e. low tPA activ-
ity [48].
The results of this study showed the increase in the
concentration of tPA antigen was not paralleled by an
increase in free tPA. Therefore, plasma tPA activity was
not increased and even declined modestly in T2D which
in accordance with pervious study [49]. The low levels
of plasma PAI-1 in T2D without MetS subjects may
have reduced the combination of PAI-1 with free tPA.
This leads to decrease the tPA/PAI-1 complex concen-
t r a t i o ni nt h i sg r o u pw i t hn od e c l i n eo rs i m p l ya n
increase in free tPA levels.
MetS is estimated to be present in 75-80% of T2D
patients and has been shown to influence CVD [50,51]
and fibrinolytic function [52,53]. In patients with MetS
but without diabetes, increased measures of athero-
sclerosis [54-56] and a higher incidence of cardiovascu-
lar events has been observed [52,57]. This has partly
been attributed to impaired fibrinolytic function [52]
due to altered regulation of PAI-1 and tPA [53,58,59].
However, treatment by a PAI-1 inhibitor improved his-
tological remodelling of myocardium and arteries with
suppression of inflammation and thrombus formation
[60]. Metabolic- defining criteria were significant predic-
tors for PAI-1 activity, while none of the diabetes
related factors seemed to contribute to PAI-1 activity
and tPA levels. Thus, the main inhibitor of fibrinolysis
was found to be severely influenced by the state of
MetS.
In some studies, decreased fibrinolysis, as measured by
high PAI-1 activity, has been associated with cardiovas-
cular events [61,62]. High levels of tPA antigen
Table 4 Correlation between PAI-1 and tPA activities and antigens and tPA/PAI-1 complex parameters among normal
group (n = 131)
Parameters Adjusted for PAI-1 activity
(IU/ml)
PAI-1 antigen
(ng/ml)
tPA activity
(U/ml)
tPA antigen
(ng/ml)
tPA/PAI-1complex
(ng/ml)
PAI-1
activity
Age, gender, race, BMI, HDL-c &
HOMA (IR)
1 0.085(0.973) 0.051(0.276) -0.100(0.598) 0.035(0.552)
PAI-1
antigen
Age, gender, race,
HDL-c & HOMA (IR)
1 0.044(0.60) 0.111(0.642) 0.029(0.03)
tPA
activity
Age, gender, race & FBS 1 -0.444
(7.7 × 10
-13)
-0.090(0.001)
tPA
antigen
Age, gender, race & IS 1 0.202(3.5 × 10
-7)
Result presented as adjusted r
2 (P-value) assessed by Linear regression. Bolt values are significant.
Table 5 Correlation between PAI-1 and tPA activities and antigens and tPA/PAI-1 complex parameters among type 2
diabetes group (n = 303)
Parameters Adjusted for PAI-1 activity
(IU/ml)
PAI-1 antigen
(ng/ml)
tPA activity (U/ml) tPA antigen
(ng/ml)
tPA/PAI-1 complex
(ng/ml)
PAI-1 activity Age, gender, race,
BMI, TG & IS
1 0.70(1.1 × 10
-36) -0.32(9.9 × 10
-12) 0.038(0.132) -0.078(0.773)
PAI-1 antigen Age, gender, race,
waist, TG & IS
1 -0.23(3.4 × 10
-6) 0.024(0.08) 0.066(0.054)
tPA activity Age, gender, race,
BMI, TG & IS
1 -0.100(5.1 × 10
-5) -0.071(0.054)
tPA antigen Age, gender, race &
HDL-c
1 0.064(7.9 × 10
-5)
Result presented as adjusted r
2 (P-value) assessed by Linear regression. Bolt values are significant.
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Page 6 of 9independently predict cardiovascular events both in a
healthy population [62,63] and in patients with prevalent
coronary disease [6,64]. Therefore, these results also
support the hypothesis that several abnormal metabolic
parameters are essential for the elevation of plasma
PAI-1 and reduction of tPA activities since PAI-1 is a
multifunctional protein. However, more studies are
needed to further assess the association between PAI-1
expression and CVD.
Conclusions
The PAI-1 activity was pronounced in MetS and T2D
with MetS whereas the tPA antigen was an indicator for
T2D without effect of MetS parameters. This impaired
fibrinolysis leads to a suggestion that coronary heart dis-
ease seems to start tick in non-diabetic MetS before the
onset of clinical diabetes. This was confirmed in quanti-
tative trait analysis in which PAI-1 activity was asso-
ciated with MetS parameters (waist, BMI, HDL-c and
insulin resistance) which are well documented as risk
factors for T2D and CVD.
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